| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
American Journal of Pathology, Vol 152, 1641-1646, Copyright © 1998 by American Society for Investigative Pathology
REGULAR ARTICLES |
DP Stevenson, SR Milligan and WP Collins
Diagnostics Research Unit, Department of Obstetrics and Gynecology, King's College School of Medicine and Dentistry, London, United Kingdom.
Platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) is associated with angiogenesis and the progression of human breast and ovarian cancers. The aim of this study was to obtain information about the possible mechanisms of PD-ECGF/TP activity in an established three-dimensional model of angiogenesis. The plan was to study the effects of the enzyme, substrate, products, and further metabolites on the formation and rate of microvessel growth from cultured segments of rat aorta in serum-free media. The end-points were the number and length of microvessels compared with controls after 4, 7, 11, and 14 days in culture. Thymidine (10 to 1000 mumol/L), thymidine-5'-monophosphate (1000 mumol/L), and 2'-deoxy-D-ribose-1- phosphate (1000 mumol/L) inhibited the number of microvessels produced. Conversely PD-ECGF/TP (50 to 100 ng/ml) and beta-amino-iso-butyric acid (1000 mumol/L--a metabolite of thymine) had a significant stimulatory effect (P < 0.05, P < 0.01, P < 0.001 respectively on culture day 11). PD-ECGF (10 ng/ml), beta-amino-iso-butyric acid (1000 mumol/L), and 2- deoxy-D-ribose (100 to 1000 mumol/L) significantly (P < 0.001, P < 0.01, P < 0.01, respectively) stimulated microvessel elongation by day 11. We conclude that PD-ECGF/TP may affect angiogenesis by changing the relative concentrations of pyrimidine-based compounds and their metabolites in interstitial fluid surrounding endothelial cells. Drugs that inhibit PD-ECGF/TP activity may therefore delay abnormal angiogenesis and the progression of various cancers.
This article has been cited by other articles:
 |
|
 |
|
  S. Liekens, A.-I. Hernandez, D. Ribatti, E. De Clercq, M.-J. Camarasa, M.-J. Perez-Perez, and J. Balzarini The Nucleoside Derivative 5'-O-Trityl-inosine (KIN59) Suppresses Thymidine Phosphorylase-triggered Angiogenesis via a Noncompetitive Mechanism of Action J. Biol. Chem., July 9, 2004; 279(28): 29598 - 29605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Yanagi, Y. Tamaki, Y. Inoue, R. Obata, K. Muranaka, and N. Homma Subconjunctival Doxifluridine Administration Suppresses Rat Choroidal Neovascularization through Activated Thymidine Phosphorylase Invest. Ophthalmol. Vis. Sci., February 1, 2003; 44(2): 751 - 754. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Haraguchi, H. Tsujimoto, M. Fukushima, I. Higuchi, H. Kuribayashi, H. Utsumi, A. Nakayama, Y. Hashizume, J. Hirato, H. Yoshida, et al. Targeted Deletion of Both Thymidine Phosphorylase and Uridine Phosphorylase and Consequent Disorders in Mice Mol. Cell. Biol., July 15, 2002; 22(14): 5212 - 5221. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Sivridis, A. Giatromanolaki, M. I Koukourakis, R. Bicknell, A. L Harris, and K. C Gatter Thymidine phosphorylase expression in normal and hyperplastic endometrium J. Clin. Pathol., September 1, 2000; 53(9): 704 - 708. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Konda, H. Sato, K. Sakai, M. Sato, S. Orikasa, and N. Kimura Expression of Platelet-Derived Endothelial Cell Growth Factor and its Potential Role in Up-Regulation of Angiogenesis in Scarred Kidneys Secondary to Urinary Tract Diseases Am. J. Pathol., November 1, 1999; 155(5): 1587 - 1597. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Stevenson, W. P. Collins, F. Farzaneh, K. Hata, and K. Miyazaki Thymidine Phosphorylase Activity and Prodrug Effects in a Three-Dimensional Model of Angiogenesis : Implications for the Treatment of Ovarian Cancer Am. J. Pathol., November 1, 1998; 153(5): 1573 - 1578. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
